BALA CYNWYD, Pa., Oct. 2, 2012 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of Ceradyne, Inc.
("Ceradyne" or the "Company") (Nasdaq- CRDN) relating to the
proposed acquisition by 3M Company ("3M").
Under the terms of the transaction, Ceradyne shareholders will
receive only $35.00 in cash for each
share of Ceradyne stock they own. The investigation concerns
possible breaches of fiduciary duty and other violations of state
law by the Board of Directors of Ceradyne for not acting in the
Company's shareholders' best interests in connection with the sale
process to 3M. The transaction may undervalue the Company and
result in a substantial loss for many Ceradyne shareholders. For
example Ceradyne stock traded at $49.40 as recently as May
10, 2011 and an analyst has set a $37.00 price target for Ceradyne.
If you own shares of Ceradyne stock and wish to discuss the
legal ramifications of the proposed transaction, or have any
questions, you may e-mail or call the law office of Brodsky &
Smith, LLC who will, without obligation or cost to you, attempt to
answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith,
LLC, Two Bala Plaza, Suite 602, Bala
Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/484-crdn-ceradyne-inc.html, by calling
toll free 877-LEGAL-90.
SOURCE Brodsky & Smith, LLC